XBiotech (XBIT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

XBIT · Stock Price

USD 2.50+0.11 (+4.60%)

Market Cap: $76.2M

Historical price data

Market Cap: $76.2MPipeline: 8 drugsFounded: 2005HQ: Austin, United States

Sector Ranking#172 in Biologics / Biosimilars

Overview

XBiotech's mission is to develop safer, more effective antibody therapies by harnessing natural human immunity, guided by a 'do no harm' principle. Its key achievement was the 2019 sale of its lead IL-1α antibody, bermekimab, for $750M upfront, providing substantial non-dilutive capital. The company's strategy leverages its fully integrated True Human™ platform—encompassing proprietary discovery (SHSAM™), genetic cloning, and in-house manufacturing—to build a pipeline targeting high-need areas in inflammation, oncology, and anti-infectives. XBiotech is now advancing multiple clinical and pre-clinical candidates from its 48-acre Austin campus.

OncologyRheumatologyNeurologyAnti-infectives

Technology Platform

The True Human™ Antibody platform discovers therapeutic antibodies by cloning native antibody genes directly from the blood of human donors with natural immunity to specific diseases, utilizing proprietary SHSAM™ mining and genetic cloning technologies.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
Natrunix with MTX placebo (+folate) + Natrunix placebo with ...	Rheumatoid Arthritis	Phase 2
Natrunix 400 mg + Placebo + Methotrexate (MTX)	Rheumatoid Arthritis	Phase 2
Natrunix + Placebo	Axial Spondyloarthritis	Phase 2
Natrunix + Placebo	Rheumatoid Arthritis	Phase 2
XB2001 or Placebo	Pancreatic Cancer	Phase 1/2

Opportunities

XBiotech's True Human™ platform offers a potential best-in-class safety profile that could disrupt large markets in inflammation and oncology, as validated by its prior $1.35B asset deal.

Its low-cost, integrated manufacturing provides a strategic advantage in production scalability and economics.

Risk Factors

The company faces binary clinical risk, as its entire value proposition depends on proving superior safety/efficacy in late-stage trials.

Its pre-revenue status and high cash burn, coupled with a volatile and depressed stock price, create significant financial and execution risks.

Competitive Landscape

XBiotech competes with dominant antibody discovery platforms (humanized/transgenic mouse, phage display) and established drugs in inflammation and oncology. Its key differentiation is the natural human source of its antibodies, claiming a potential safety advantage over all marketed 'fully human' engineered alternatives.